12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Regorafenib regulatory update

FDA granted Orphan Drug designation for Bayer's regorafenib to treat gastrointestinal stromal tumors (GIST)....

Read the full 47 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >